Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Spherix Inc (SPEX)

Spherix Inc (SPEX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,865
  • Shares Outstanding, K 4,825
  • Annual Sales, $ 10 K
  • Annual Income, $ -4,180 K
  • 60-Month Beta 0.04
  • Price/Sales 1,066.86
  • Price/Cash Flow N/A
  • Price/Book 0.75
Trade SPEX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.25
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 03/17/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6500 +150.77%
on 03/05/20
5.5200 -70.47%
on 03/09/20
+0.6400 (+64.38%)
since 02/12/20
3-Month
0.6500 +150.77%
on 03/05/20
5.5200 -70.47%
on 03/09/20
+0.4600 (+39.35%)
since 12/12/19
52-Week
0.6500 +150.77%
on 03/05/20
5.5200 -70.47%
on 03/09/20
-1.8100 (-52.65%)
since 03/12/19

Most Recent Stories

More News
Spexis provides business update

Ad hoc announcement pursuant to Art. 53 LR...

SPEX : 1.6300 (-18.09%)
Spexis announces business update call to be held on July 28th

Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET...

SPEX : 1.6300 (-18.09%)
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its...

SPEX : 1.6300 (-18.09%)
Spexis to Present at H.C. Wainwright Global Investment Conference

ALLSCHWIL, Switzerland, May 19, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright...

SPEX : 1.6300 (-18.09%)
Spexis to Present at BioEquity Europe 2022

ALLSHWIL, SWITZERLAND / ACCESSWIRE / May 12, 2022 / Spexis AG (SIX: SPEX) today announced that that the company will present at BioEquity Europe, taking place May 17 & 18, 2022. Jeff Wager, CEO of Spexis,...

SPEX : 1.6300 (-18.09%)
Spexis Annual General Meeting 2022

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, SWITZERLAND / ACCESSWIRE / April 27, 2022 / Spexis AG (SIX:SPEX) today announced that its shareholders approved all proposals of the Board of Directors...

SPEX : 1.6300 (-18.09%)
Spexis Publishes Invitation to Annual General Meeting 2022

Ad hoc announcement pursuant to Art. 53 LR - Pre-AGM information call on April 7, 2022 at 2:30PM CET - AGM to be held April 26, 2022 - Shareholders not physically present, in accordance with COVID-19 ordinances...

SPEX : 1.6300 (-18.09%)
Spexis Provides Business Update and Announces Financial Results for the Full-Year 2021

- Successful launch of Spexis AG as a reverse merger of Polyphor AG with EnBiotix Inc. - Successful closing of a USD 12.8 million pre-merger financing - First patient enrollment and start of Phase 1 trial...

SPEX : 1.6300 (-18.09%)
Spexis to Present Strategy Update and Full-Year 2021 Financial Results on March 24, 2022

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, SWITZERLAND / ACCESSWIRE / March 9, 2022 / Spexis AG (SIX:SPEX) announced today that it will publish its full-year financial results for 2021 on March...

SPEX : 1.6300 (-18.09%)
Spexis Achieves First CARB-X Milestone for its Thanatin Derivatives Program and Receives Funding of up to USD 1.9 Million to Initiate Lead Optimization

ALLSCHWIL, SWITZERLAND / ACCESSWIRE / March 3, 2022 / Spexis AG (SIX:SPEX) announced today that it has been awarded the second part of its phased funding grant from CARB-X (Combating Antibiotic-Resistant...

SPEX : 1.6300 (-18.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Spherix is a technology innovations company. The Company consists of aBiotechnology Division (BioSpherix), a Commercial Information Services Division (CISD), a Government Information Services Division (GISD), and an Information Technology Division (ITD). CISD, GISD and ITD are collectively referred...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 2.1600
1st Resistance Point 1.8900
Last Price 1.6300
1st Support Level 1.4700
2nd Support Level 1.3200
3rd Support Level N/A

See More

52-Week High 5.5200
Fibonacci 61.8% 3.6600
Fibonacci 50% 3.0900
Fibonacci 38.2% 2.5100
Last Price 1.6300
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar